Vor Biopharma Inc. (VOR) — SEC Filings
Vor Biopharma Inc. (VOR) — 48 SEC filings. Latest: 4 (Apr 24, 2026). Includes 28 8-K, 6 10-Q, 3 4.
View Vor Biopharma Inc. on SEC EDGAR
Overview
Vor Biopharma Inc. (VOR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: Vor Biopharma Inc. (VOR) reported significant strategic shifts in its 2025 fiscal year, in-licensing telitacicept from RemeGen Co., Ltd. in June 2025 for exclusive development and commercialization outside Greater China. Telitacicept, a novel fusion protein targeting BAFF and APRIL, is already appro
Sentiment Summary
Across 48 filings, the sentiment breakdown is: 1 bullish, 5 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Vor Biopharma Inc. is neutral.
Filing Type Overview
Vor Biopharma Inc. (VOR) has filed 3 4, 1 S-8, 3 10-K, 28 8-K, 6 10-Q, 3 DEF 14A, 2 SC 13G/A, 1 10-Q/A, 1 SC 13D/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (48)
Risk Profile
Risk Assessment: Of VOR's 40 recent filings, 6 were flagged as high-risk, 24 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | Not Disclosed |
| Net Income | Not Disclosed |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | Not Disclosed |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Board of Directors
- Dr. Christopher Starr
- Dr. Robert Valeriote
- Dr. David Ma
- Andrew J. Schwab
- Dr. Kush Parmar
- Paul A. Stone
- Abigail P. Johnson
Industry Context
The biopharmaceutical industry, particularly in the autoimmune and rare disease space, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like Vor Bio operate in a competitive landscape where innovation in targeted therapies is crucial. The success of novel biologics often depends on demonstrating clear clinical differentiation and addressing unmet medical needs. The market for treatments for diseases like gMG and SjD is growing, driven by increased understanding of disease mechanisms and patient demand for more effective therapies.
Top Tags
management-change (8) · Biotechnology (5) · 10-Q (5) · material-agreement (4) · equity-sale (4) · governance (4) · corporate-governance (4) · financials (4) · Clinical Trials (3) · officer-changes (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of common stock held by non-affiliates | $76.1 million | as of June 30, 2025, indicating current market valuation |
| Shares of Common Stock outstanding | 48,847,504 | as of March 23, 2026 |
| Mean MG-ADL change from baseline | -7.5 | for continuous telitacicept patients at week 48 in China Phase 3 gMG trial, indicating symptom improvement |
| Percentage of continuous telitacicept patients achieving 3-point MG-ADL improvement | 96.2% | at week 48 in China Phase 3 gMG trial, demonstrating high response rate |
| Mean QMG change from baseline | -9.8 | for continuous telitacicept patients at week 48 in China Phase 3 gMG trial, indicating disease severity reduction |
| Percentage of continuous telitacicept patients achieving 5-point QMG improvement | 94.2% | at week 48 in China Phase 3 gMG trial, showing strong objective improvement |
| Fiscal year ended | 2025 | the period covered by this 10-K filing |
| Filing date of 10-K | 2026-03-30 | the date this annual report was submitted to the SEC |
| SEC Accession Number | 0001193125-26-127609 | Unique identifier for this specific SEC filing |
| File Number | 001-39979 | SEC file number associated with Vor Biopharma Inc. |
| Report Date | 2025-12-15 | Date of the earliest event reported in the 8-K filing. |
| Net Loss | $2.419B | Increased from $86.202M in 2024 for the nine months ended September 30, 2025, primarily due to warrant liabilities. |
| Change in Fair Value of Warrant Liabilities | $2.090B | Major driver of the increased net loss for the nine months ended September 30, 2025. |
| Research and Development Expenses | $302.342M | Increased from $67.962M in 2024 for the nine months ended September 30, 2025, indicating higher pipeline investment. |
| Accumulated Deficit | $2.876B | As of September 30, 2025, reflecting significant historical losses. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant ownership stake in Vor Biopharma Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"The continued institutional backing from FMR LLC will contribute to market stability for Vor Biopharma's stock.","entity":"Vor Biopharma Inc.","targetDate":"2024-08-09","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Vor Biopharma Inc. (VOR)?
Vor Biopharma Inc. has 48 recent SEC filings from Jan 2024 to Apr 2026, including 28 8-K, 6 10-Q, 3 4. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VOR filings?
Across 48 filings, the sentiment breakdown is: 1 bullish, 5 bearish, 41 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Vor Biopharma Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vor Biopharma Inc. (VOR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vor Biopharma Inc.?
Key financial highlights from Vor Biopharma Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VOR?
The investment thesis for VOR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vor Biopharma Inc.?
Key executives identified across Vor Biopharma Inc.'s filings include Board of Directors, Dr. Christopher Starr, Dr. Robert Valeriote, Dr. David Ma, Andrew J. Schwab and 3 others.
What are the main risk factors for Vor Biopharma Inc. stock?
Of VOR's 40 assessed filings, 6 were flagged high-risk, 24 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Vor Biopharma Inc.?
Recent forward-looking statements from Vor Biopharma Inc. include guidance on {"claim":"FMR LLC will maintain a significant ownership stake in Vor Biopharma Inc. for the foreseeable future.","entity and 1 other predictions.